1. Scrip
  2. >>Archive

Teva launches Yaz generic in the US, triggering patent infringement suit by Bayer

 
• By Nancy Faigen

Teva Pharmaceutical Industries has launched its own generic version of Bayer's oral contraceptive, Yaz (drospirenone plus ethinyl estradiol), in the US to be sold under the brand-name Gianvi. The move immediately triggered a patent infringement lawsuit from Bayer, which has accused Teva of infringing three patents that expire in June 2014. Yaz is the top-selling birth control pill in the US.

Teva Pharmaceutical Industries has launched its own generic version of Bayer's oral contraceptive, Yaz (drospirenone plus ethinyl estradiol), in the US to be sold under the brand-name Gianvi. The move immediately triggered a patent infringement lawsuit from Bayer, which has accused Teva of infringing three patents that expire in June 2014. Yaz is the top-selling birth control pill in the US.

The complaint, filed by Bayer Schering Pharma in the US District court for the District of Delaware, seeks to block Teva from selling its own version until the patents expire

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.